UDCA AND METHOTREXATE FOR PRIMARY BILIARY CIRRHOSIS

UDCA 和甲氨蝶呤治疗原发性胆汁性肝硬化

• 批准号: 6117536
• 负责人: BURTON COMBES
• 金额: $ 3.48万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117536
• 关键词: biliary tract disorder chemotherapy; clinical research; combination chemotherapy; human subject; human therapy evaluation; methotrexate; primary biliary cirrhosis; ursodeoxycholate

There is no known specific treatment for PBC at present. UDCA and methotrexate may be useful in the treatment of this autoimmune disease. This study will examine whether treatment with UDCA and methotrexate is better than treatment with UDCA alone.

目前尚无针对PBC的特定治疗方法。 UDCA和甲氨蝶呤可能对治疗这种自身免疫性疾病有用。这项研究将检查使用UDCA和甲氨蝶呤治疗是否比单独使用UDCA治疗更好。